Accessibility Menu
 
Arrow-Thin-Down
S&P 500
6,816.89
-0.1%
-7.77
Arrow-Thin-Down
DJI
47,916.57
-0.6%
-269.23
Arrow-Thin-Down
NASDAQ
22,902.89
+0.4%
+80.48
Arrow-Thin-Down
Bitcoin
$70,818.00
-1.3%
-$928.30
Arrow-Thin-Down
AMZN
$238.38
+2.0%
+$4.73
Arrow-Thin-Down
GOOG
$315.72
-0.2%
-$0.65
Arrow-Thin-Down
META
$629.75
+0.2%
+$1.36
Arrow-Thin-Down
MSFT
$370.82
-0.6%
-$2.25
Arrow-Thin-Down
NVDA
$188.67
+2.6%
+$4.76
Arrow-Thin-Down
TSLA
$348.76
+0.9%
+$3.14
Most Active StocksDaily Stock GainersDaily Stock Losers

Is Novo Nordisk a No-Brainer Buy After It Dropped 40%?

By Neil Rozenbaum – Mar 19, 2025 at 5:00AM EST

In this video, I will cover the recent updates regarding Novo Nordisk (NVO +0.25%). Watch the short video to learn more, consider subscribing, and click the special offer link below.

*Stock prices used were from the trading day of March 17, 2025. The video was published on March 18, 2025.

Read Next

Neil Rozenbaum has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Stocks Mentioned

Novo Nordisk Stock Quote
Novo Nordisk
NYSE: NVO
$37.52
(+0.21%)+$0.08
Viking Therapeutics Stock Quote
Viking Therapeutics
NASDAQ: VKTX
$34.26
(-1.97%)-$0.69

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services